Coronaviruses

Progress of Section “Biochemistry” in 2022

“…Interesting SARS-CoV-2 main protease inhibitors were reported by Geiger et al [ 45 ], whereas Ma et al [ 46 ] identified darunavir derivatives which effectively inhibit the cysteine-like protease of this virus. Many studies on monoclonal antibodies targeting various proteins of the virus were also ultimately published [ 47 , 48 , 49 , 50 , 51 ], although the role of these therapeutics in the management of COVID-19 was very much re-dimensioned due to mutations and loss of efficacy as well as the design of small molecule inhibitors targeting various viral proteins [ 52 , 53 ]. An interesting review on the other virus which worried the world in the last year, monkeypox, has also been timely published in the journal [ 54 ].…”

Identification of sulphonamide-tethered N -((triazol-4-yl)methyl)isatin derivatives as inhibitors of SARS-CoV-2 main protease

“…There are now only a few SARS-CoV-2 medicines available, despite the widespread approval of vaccination 3 , 4 . In addition to this, the emergence of SARS-CoV-2 omicron subvariants that are effective poses a threat to the efficacy of vaccines developed for the purpose of controlling COVID-19 infection 5 , 6 . Hence, the search for effective therapeutic drugs to combat SARS-CoV-2 is urgently needed.…”